In the AD group, the two biomarker levels did not significantly correlate, indicating that lower CSF LCN2 levels might be associated with the presence of AD-related pathology in a clinically defined MCI group rather than with the levels of Abeta42 in a homogenous AD group. The gene discussed is LCN2; the disease is Alzheimer disease.